Pharvaris is a pre-revenue biotechnology company advancing its lead asset, PHA121, for hereditary angioedema, with its investment thesis hinged on the successful Phase 3 clinical execution and potential commercial launch. The primary growth driver is the progr...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.81-8.5% vs -$0.75 | — vs — |
Q2 2026 May 12, 2026 | -$0.70+14.8% vs -$0.82 | — vs — |
Q2 2026 Apr 2, 2026 | -$0.85-18.3% vs -$0.71 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.70+10.3% vs -$0.78 | — vs — |
Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.56, for a total transaction of $558,850.08. Following the sale, the director owned 10,500 shares of the company's stock, valued at $404,880. The
Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 20,000 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $38.27, for a total transaction of $765,400.00. Following the completion of the sale, the insider directly owned 73,969 shares in the company,
Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued
Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the company's stock after selling 51,755 shares during the period. Squarepoint Ops LLC owned approximately 0.07% of Pharvaris
Benchmark PHVS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pharvaris N.V. (PHVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.07 | $2.31B | -9.78 | — | — | -65.19% | — | |
| $27.00 | $1.44B | -8.36 | — | -119.44% | -1057.44% | — | |
| $1.74 | $2.88M | -0.03 | -81.82% | -370.05% | — | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $3.48 | $859.66M | -13.38 | 22.09% | -12.35% | -36% | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — |
Pharvaris N.V. (PHVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PHVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pharvaris N.V. (PHVS) stock FAQ — growth, dividends, profitability & financials explained
Pharvaris N.V. (PHVS) reported a net loss of $171.6M for fiscal year 2025.
Pharvaris N.V. (PHVS) has a return on equity (ROE) of -65.2%. Negative ROE indicates the company is unprofitable.
Pharvaris N.V. (PHVS) had negative free cash flow of $156.1M in fiscal year 2025, likely due to heavy capital investments.
